Last week, Health Canada notified non-profit organization Therapsil that it intended to deny Section 56 exemptions for 130 healthcare practitioners seeking psilocybin access and training.
Since 2019, Therapsil has successfully advocated for patients and healthcare practitioners interested in pursuing psilocybin therapy and helped a group of practitioners obtain exemptions in December 2020. The Dales Report sat down with CEO Spencer Hawkswell on Friday to try and understand the potential impact of the federal health agency’s intent to deny.
Share this post
